JAZZ

JAZZ

USD

Jazz Pharmaceuticals plc Common Stock (Ireland)

$110.800+2.280 (2.101%)

Цена в режиме реального времени

Healthcare
Биотехнология
Ирландия

График цен

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$108.520

Максимум

$111.170

Минимум

$107.660

Объем

0.00M

Фундаментальные показатели компании

Рыночная капитализация

6.7B

Отрасль

Биотехнология

Страна

Ireland

Статистические данные торговли

Средний объем

1.16M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $95.49Текущая $110.800Максимум $148.06

Связанные новости

PR Newswire

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Просмотреть больше
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
PR Newswire

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present seven abstracts at the American...

Просмотреть больше
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
PR Newswire

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after...

Просмотреть больше
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
PR Newswire

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc....

Просмотреть больше
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Analyst Upgrades

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals with a Buy and maintains $210 price target.

Просмотреть больше
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.